The Conference 

The 2020 edition features dedicated tracks on Evidence (including Real World Evidence), Big Data, Digital Health & Analytics, Value, Pricing & Market Access, Affordability, Contracting, as well as a focus on therapeutic areas including Rare Diseases, Advanced Therapies, BioSimilar, and more. 


Track 1: Evidence, Capability-building & RWE  

Gain the latest guidance and insight on how to use evidence and RWE effectively

Track 2: Pricing & Market Access  

Explore practical case studies from senior pharma/biotech, payer & HTA representatives on improving your access & pricing strategies

Track 3: Rare Diseases  

Learn about new market access, regulatory and innovative developments in the world of orphan drugs & rare diseases

Track 4: Big Data, Digital Health & Analytics  

Come and listen to speakers who are shaping technological innovation and harnessing digital health, analytics and AI to improve outcomes in access, pricing and evidence

Track 5: HTA 

Hear from HTA’s such as AIFA and the Ministry of Health of Russia on achieving greater collaboration and a better understanding of their HTA policies

Track 6: Advanced Therapies 

The Advanced Therapies work session highlights the latest updates taking place in cell & gene therapies, explores the regulatory challenges and celebrates the innovation

Track 7: Managed Entry Agreements 

Gain insight from pharma, patient groups and payers about their involvement in negotiating managed entry agreements

Track 8: Emerging Markets, Far East Asia & Australasia 

Listen to the latest market access and pricing developments in Africa, Latin America, Middle East, Far East Asia and Australia

Track 9: Affordability 

Explore the political factors and health outcomes when considering affordability 

Track 10: Biosimilars 

Examine the sustainability of biosimilars and latest regulation shaping the industry


Contact us

To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052

To speak:
Chris Shanks
+44 (0)207 092 1151